RAFA OTC
Rafarma Pharmaceuticals, Inc.
1W: -13.5%
1M: +6.7%
3M: +60.0%
YTD: +17.0%
1Y: -33.3%
3Y: -86.1%
5Y: -97.4%
$0.03
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$9M
-10.4% ▼
5Y CAGR: -4.5%
Gross Profit
$674K
+12.3% ▲
5Y CAGR: -27.5%
Operating Income
$405K
+29.4% ▲
5Y CAGR: -33.4%
Net Income
$266K
-2.6% ▼
5Y CAGR: -38.6%
EPS (Diluted)
$0.00
-3.2% ▼
5Y CAGR: -38.0%
EBITDA
$342K
-4.7% ▼
5Y CAGR: -37.4%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $75M | $77M | $64M | $10M | $9M |
| YoY Growth | +553.1% | +3.6% | -16.9% | -84.2% | -10.4% |
| Cost of Revenue | $42M | $50M | $42M | $10M | $8M |
| Gross Profit | $33M | $27M | $23M | $600K | $674K |
| Gross Margin | 44.3% | 35.2% | 35.5% | 5.9% | 7.4% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $8M | $5M | $5M | $150K | $148K |
| Operating Expenses | $14M | $13M | $16M | $287K | $269K |
| Operating Income | $19M | $15M | $7M | $313K | $405K |
| Operating Margin | 25.5% | 19.0% | 11.1% | 3.1% | 4.5% |
| Interest Expense | $7K | $0 | $0 | $0 | $0 |
| Income Before Tax | $19M | $15M | $6M | $360K | $343K |
| Tax Expense | $4M | $3M | $1M | $87K | $77K |
| Net Income | $15M | $12M | $5M | $273K | $266K |
| Net Margin | 19.9% | 15.0% | 7.7% | 2.7% | 2.9% |
| EPS (Diluted) | $0.17 | $0.13 | $0.06 | $0.00 | $0.00 |
| EBITDA | $19M | $15M | $6M | $527K | $342K |
| Shares Outstanding | 88M | 88M | 88M | 88M | 88M |